At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 200 enrolled
Drug / intervention
Alemtuzumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols Accompanied by Maintenance Therapy With Prograf® and Myfortic®
In Brief
A Phase 4 clinical trial evaluating Alemtuzumab, Daclizumab, and 1 other intervention for Transplant; Failure, Kidney. Completed, enrolled 200 participants across 1 site.
Detailed Summary
The purpose of the present study is to determine which antibody induction regimen will result in a safer and more effective method to use with steroid avoidance in renal transplant recipients. Patients receiving either first cadaveric or non-HLA identical living donor kidney transplants will be preoperatively randomized into 2 groups.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTransplant; Failure, Kidney
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2006
Primary CompletionMay 2010
First PostedJul 2010
TodayJul 2026
First PostedJul 29, 2010
Enrollment StartFeb 1, 2006
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 15.9 years ago
Interventions
Alemtuzumabdrug
Alemtuzumab used as part of combined Induction.
Daclizumabdrug
Daclizumab used as part of combined induction.
Thymoglobulindrug
Thymoglobulin used as part of combined induction.